Anzeige
Mehr »
Login
Sonntag, 11.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Kurseskalation am Montag? Diese Gamechanger-News macht es möglich!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEFW ISIN: KYG2588M1006 Ticker-Symbol: PH4 
Tradegate
09.04.21
20:18 Uhr
1,030 Euro
-0,030
-2,83 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CSTONE PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
CSTONE PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,0001,04010.04.
0,9951,03009.04.

Aktuelle News zur CSTONE PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.CSTONE PHARMA-B (02616): GRANT OF SHARE OPTIONS9
31.03.CSTONE PHARMA-B (02616): INSIDE INFORMATION - BUSINESS UPDATES14
26.03.AKTIONÄR-Hot-Stock CStone: Pfizer-Beteiligung mit Top-News535In Ausgabe 05/2021 hat DER AKTIONÄR erstmals die Aktie von CStone in der Rubrik "Hot-Stock der Woche" vorgestellt. Seitdem hat sich der exotische Biotech-Wert in einem schwierigen Marktumfeld nicht...
► Artikel lesen
CSTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
26.03.CSTONE PHARMA-B FY20 Loss Trims to RMB1.22B21
25.03.CSTONE PHARMA-B (02616): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 202012
24.03.Blueprint Medicines partner CStone wins Chinese approval for lung cancer therapy12
24.03.CStone Pharma (02616): inhibitor gets approval from NMPA7
24.03.CSTONE PHARMA-B (02616): INSIDE INFORMATION - BUSINESS UPDATES9
15.03.CSTONE PHARMA-B (02616): DATE OF BOARD MEETING22
08.03.CSTONE PHARMA-B (02616): CHANGE OF BUILDING NAME OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG28
08.02.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES ANOTHER BREAKTHROUGH THERAPY DESIGNATION GRANTED FOR SUGEMALIMAB REPRESENTING A NEW BREAKTHROUGH IN THE TREATMENT OF RELAPSED AND REFRACTORY ...78
28.01.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE REPORTS EFFICACY AND SAFETY DATA FROM THE ARROW TRIAL OF PRALSETINIB IN CHINESE PATIENTS WITH ADVANCED RET FUSION-POSITIVE NSCLC AFTER PLATINUM-BASED ...91
10.12.20CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE'S PARTNER BLUEPRINT MEDICINES ANNOUNCED U.S. FDA HAS APPROVED GAVRETO (PRALSETINIB) FOR THE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC ...36
30.11.20CSTONE PHARMA-B (02616): GRANT OF OPTIONS PURSUANT TO THE POST-IPO ESOP AND GRANT OF RSU PURSUANT TO THE POST-IPO RSU SCHEME5
30.11.20CSTONE PHARMA-B (02616): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION3
30.11.20CSTONE PHARMA-B (02616): APPOINTMENT AND RESIGNATION OF NON-EXECUTIVE DIRECTORS2
23.11.20CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE RESULTS OF GEMSTONE-302 SUGEMALIMAB HAS THE POTENTIAL TO PROVIDE A NEW TREATMENT OPTION FOR PATIENTS WITH ADVANCED NSCLC3
20.11.20CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - GLOBAL STRATEGIC PARTNERSHIP BETWEEN CSTONE AND EQRX TAKES EFFECT FOLLOWING EARLY TERMINATION OF HSR WAITING PERIOD4
12.11.20CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CHINA'S NMPA HAS ACCEPTED NDA FOR ANTI-PD-L1 MONOCLONAL ANTIBODY SUGEMALIMAB (CS1001) IN FIRST-LINE ADVANCED NSCLC3
10.11.20CStone Pharma (02616) submits new drug application2
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,16